

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

Army 160

In Re Application Of: **Sherman**

Serial No.

09/544,108

Filing Date

April 6, 2000

Examiner

Wortman, D.

Group Art Unit

1648

Title: **Composition and Method f Treating Hepatitis C**

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);**OR**☒ the fee set forth in 37 CFR 1.17(p).

05/13/2002 NVILLARI 00000004 210380 09544108

01 FC:126 160.00 CH

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

Army 160

In Re Application: Sherman

Serial No.

09/544,108

Filing Date

April 6, 2000

Examiner

Wortman, D.

Group Art Unit

1648

Composition and Method f Treating Hepatitis C

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$180.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F _____)


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited 5-2-02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.




Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: 5-2-02

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC


3415 Brookeville Road

Brookeville, MD 20833

(301) 924-9500

CC:

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)



Docket Number (Optional)

Army 16

Application Number

09/544,108

Applicant(s)

Sherman

Filing Date

April 6, 2000

Group Art Unit

1648

PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	5,849,696	12/15/98	Chretien et al.	514	12	11/4/93
	B	4,079,127	3/14/78	Goldstein et al.	424	177	2/8/77
	C	5,308,833	5/3/94	Scharschmidt et al.	514	12	2/6/92
	D	5,467,729	11/21/95	Chretien, et al.	514	2	10/26/93

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

aa	Lok, et al., Long-Term Follow-Up in a Randomised Controlled Trial of Recombinant Alpha2-Interferon in Chinese Patients With Chronic Hepatitis B Infection, Lancet, 1988, 2: 298-302
bb	Garcia, et al., Adenine Arabinoside Monophosphate (Vidarabine Phosphate) combination with Human Leukocyte Interferon in the Treatment of Hepatitis B, Annals of Internal Medicine, 1987: 107: 278-285.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

Army 160

Application Number

09/544,108

Applicant(s)



Sherman

Filing Date

April 6, 2000

Group Art Unit

1648



*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
cc	Huang, et al., Thymosin Treatment Modulates Production of Interferon, J. of Interferon Research, Vol. 1, Number 3, 1981
dd	Lok, et al., Interferon Antibodies may Negate the Antiviral Effects of Recombinant Alpha-Interferon Treatment in Patients with Chronic Hepatitis B Virus Infection, Hepatology, Vol. 12, No. 6, 1990
ee	Mutchnick, et al., Thymosin Treatment of Chronic Hepatitis B: a Placebo-Controlled Pilot Trial, Hepatology, 1991, Sep; 14(3): 409-415.
ff	Bodenheimer, et al., A Randomized, Controlled Trial of Interferon Alfa-2b Alone and After Prednisone Withdrawal For The Treatment of Chronic Hepatitis B, New England Journal of Medicine; Aug. 2, 1990, 295-301.
gg	Lok, et al., Thrice Weekly Lymphoblastoid Interferon is Effective in Inhibiting Hepatitis B Virus Replication, Liver, 1984; 4: 45-49.
hh	Rasi, et al., Combined Treatment with THymosin Alpha1 and Interferon-Alpha in B and C Virus Chronic Hepatitis, Third International Symposium on Combination Therapies, October 29-312, 1993.
ii	Virgilio, et al., Treatment of Chronic Viral Hepatitis C with Thimosinn Alpha1 (TA1) and IFNAlpha: Preliminary Results, Second International Symposium on Combination Therapies, May, 1992.
jj	Garaci, combination Therapy with Thymic Hormone and Interferon in Chronic B Virus Hepatitis; First International Symposium on combination Therapies, March, 1991.
kk	Weiland, O., Interferon Therapy in Chronic Hepatitis C Virus Infection, FEMS Microbiology Reviews 14 (1994) 279-288.
ll	Rubin, et al., Chronic Hepatitis C, Arch Intern Med, Vol. 154, Feb 28, 1994.
mm	The A, B, C, D and E of Viral Hepatitis from the National Institutes of Dental Research, December 22, 1997.
nn	The Virus and its Components, 7/15/98

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army 160

Application Number

09/544,108

Applicant(s)

Sherman

Filing Date

April 6, 2000

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

oo

Davis, G. Hepatitis C: Therapy, Information on the Liver in Health and Disease, ALF Professional Education., 1997.

pp

Huang, Followed-up Observation on Antiviral Effect of combined Treatment of Small Dosage of Interferon and Thymosin in Patients With Chronic Hepatitis B, Biosis., 1997, Abstract.

qq

Rudinger, Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence; p. 1-7; Peptide H., (1986)

rr

Hoofnagle, Treatment of Chronic Type C Hepatitis with Alpha Interferon; Seminars in Liver Disease; vol. 9; no. 4(1989)

ss

Hoofnagle, et al.; Randomized, Controlled Trial of Recombinant Human Alpha-Interferon in Patients with Chronic Hepatitis B; Gastroenterology; 1988; 95: 1318-1325.

tt

Perrillo; Treatment of Chronic Hepatitis B with Interferon; Experience in Western Countries; Seminars in Liver Disease; vol. 9; no. 4, 1989

uu

Davis; Editorial, Treatment of Chronic Hepatiti B; vol. 14; vo. 3, 1991

vv

Davis; Interferon in Viral Hepatitis: Role in Pathogenesis and Treatment; Hepatology; vol. 6; vo. 5, -pp 1038-1041, 1986.

ww

Mutchnick, et al.; Thymosin Treatment of Chronic Hepatitis B: A Placebo controlled Pilot Trial; Hepatology; vol. 14, No. 3, 1991.

xx

Kakumu, Effect of Ribavirin and IFNB Therapy for Chronic Hepatitis B; vol. 44 (date?)

yy

Janssen, Antiviral Combination Therapy of Alpha-Interferon and Zidovudine in Chronic Hepatitis Type B: Results from Randomized Controlled; 100 (date?)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.